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Somatic Mutation of GRIN2A in Malignant
Melanoma Results in Loss of Tumor Suppressor
Activity via Aberrant NMDAR Complex Formation
Todd D. Prickett1, Brad J. Zerlanko1, Victoria K. Hill1, Jared J. Gartner1, Nouar Qutob2, Jiji Jiang1,
May Simaan3, John Wunderlich4, J. Silvio Gutkind3, Steven A. Rosenberg4 and Yardena Samuels1,2
The ionotropic glutamate receptors (N-methyl-D-aspartate receptors (NMDARs)) are composed of large
complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx
or efflux of mono- or divalent cations (e.g., Ca2þ ) important for synaptic transmissions, cellular migration, and
survival. Recently, we discovered the high prevalence of somatic mutations within one of the ionotropic
glutamate receptors, GRIN2A, in malignant melanoma. Functional characterization of a subset of GRIN2A mutants
demonstrated a loss of NMDAR complex formation between GRIN1 and GRIN2A, increased anchorage-
independent growth in soft agar, and increased migration. Somatic mutation of GRIN2A results in a dominant
negative effect inhibiting the tumor-suppressive phenotype of wild-type (WT) GRIN2A in melanoma. Depletion of
endogenous GRIN2A in melanoma cells expressing WT GRIN2A resulted in increased proliferation compared
with control. In contrast, short-hairpin RNA depletion of GRIN2A in mutant cell lines slightly reduced
proliferation. Our data show that somatic mutation of GRIN2A results in increased survival, and we demonstrate
the functional importance of GRIN2A mutations in melanoma and the significance that ionotropic glutamate
receptor signaling has in malignant melanoma.
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INTRODUCTION
Glutamate receptors are involved in cell homeostasis, cell
growth, neurotransmission, cell survival, and programmed cell
death (Komuro and Rakic, 1993; Kaderlik et al., 1994; Nacher
and McEwen, 2006; Schlett, 2006; Wang et al., 2007).
Glutamate receptors are composed of two different major
types; the ionotropic and the metabotropic family (Stepulak
et al., 2009). Ionotropic glutamate receptors (e.g., N-methyl-
D-aspartate (NMDA) receptors) are composed of large
complexes of multi-protein subunits creating ion channels in
the cell plasma membranes allowing influx or efflux of mono-
or divalent cations (e.g., Ca2þ ) (Monyer et al., 1992). Upon
binding of glutamate and glycine, these ligand-gated ion
channels change their conformation resulting in ion
permeability and intracellular oscillations that, in many
neuronal cells (cerebellar granule cells, neurons, astrocytes,
and glial cells), are important for synaptic transmissions,
cellular migration, and survival (Komuro and Rakic, 1993;
Lau and Tymianski, 2010; Traynelis et al., 2010).
The NMDA receptor has a major role in many neuronal
processes and disease etiologies such as learning, memory,
and neurodegeneration (i.e., Schizophrenia; Lang et al., 2007).
The NMDARs are heterotetrameric complexes consisting of
two NR1 (GRIN1) subunits and two NR2 (GRIN2 (A–D)),
or a mixture of GRIN2 and GRIN3 subunits predominately
expressed in neuronal cells. Upon binding of its cognate
ligands, NMDAR permits Ca2þ influx resulting in increased
intracellular calcium levels leading to activation of calcium-
dependent signal transduction (Traynelis et al., 2010).
However, hyperactivation of NMDAR by glutamate leads to
calcium-dependent cell death (excitotoxicity), a phenomenon
observed in neurodegenerative diseases and brain tumors
(Ye and Sontheimer, 1999; Takano et al., 2001). Recent
studies have demonstrated the importance of functional
NMDA receptors in neurological systems. GRIN2A and
GRIN2B were found to be mutated in Schizophrenia
patients and patients with epilepsy causing decreased
channel permeation (Endele et al., 2010; Carvill et al., 2013;
Lemke et al., 2013; Lesca et al., 2013). The implication that
the NMDA receptor functions as a conveyor of cellular signals
important for cognitive learning and apoptosis has been well
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established in neuronal diseases and brain tumors (Rzeski
et al., 2001; Hahn et al., 2006; Lau and Tymianski, 2010).
Interestingly, glioma cells (either in culture or in patients)
secrete excess glutamate to the extracellular milieu (composed
of many cell types including glial and neuronal) (Ye and
Sontheimer, 1999) causing overstimulation of glutamate
receptors on neurons leading to increased Ca2þ -mediated
apoptosis, allowing glioma cells room to grow and spread
(Takano et al., 2001).
Recently, our lab demonstrated through whole-exome
sequencing a high prevalence of somatic mutations in
GRIN2A in malignant melanoma (Wei et al., 2011). Whole-
exome sequencing of our matched samples revealed the
unexpected discovery that GRIN2A was somatically mutated
in B25% of the melanoma cases. The mutations were
distributed throughout the gene, with clustering of mutations
at amino acids within important functional domains (e.g., the
ligand binding domain). We also observed three recurrent
alterations at S278F, E371K, and E1175K as well as five
nonsense mutations. Recently, another group recently
published a whole-exome screen of eight melanoma
samples and found two additional somatic mutations in
GRIN2A, suggesting that genetic alteration of this gene is
important (Stark et al., 2011). Furthermore, seven somatic
mutations found in our screen have been discovered by
others as well as some listed in the COSMIC database
(D252N, S278F, W343X, G449E, M653I, R920K, S929F,
and E1073K; Berger et al., 2012; Hodis et al., 2012) (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Taken
together with the recent publication of mutations found in
Schizophrenic patients and our data we decided to analyze
how these mutations affected GRIN2As function giving us
a better understanding of how NMDA receptors work in
melanomagenesis.
RESULTS
To determine how somatic mutations in the NMDA receptor
subunit GRIN2A effect the functioning of NMDARs (e.g.,
complex formation or cation influx), we cloned specific
mutations based on location within important functional
domains or if they truncated the protein product (see sche-
matic in Supplementary Figure S1 online). We used wild-type
(WT) GRIN2A to insert mutations and first examined complex
formation between GRIN1 and GRIN2A using a transient
expression assay. HEK293T cells were transiently co-trans-
fected with WT GRIN1 with GRIN2A (WT, E371K, W372X,
E373K, G889E, Q891X, R920K, E1172K, or W1271X) or
empty vector control and further tested for complex formation
via co-immunoprecipitation using anti-GRIN1 (Figure 1a). As
can be seen, WT GRIN1 precipitated WT GRIN2A and to a
lesser extent GRIN2A (W1271X). However, the rest of the
mutations in GRIN2A had very little to no association with
GRIN1 in vitro. To rule out a lack of protein expression in
these cells we probed cell lysates from the same experiment
with anti-GRIN2A and found equal expression (Figure 1a
bottom panel). We probed for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a loading control. Furthermore,
we tested complex formation now focusing on protein–protein
binding between GRIN1 and GRIN2A precipitating with
GRIN2A and probing for GRIN1. HEK293T cells were
transiently co-transfected with GRIN1 and GRIN2A (WT,
W372X, Q891X, R920K, W1271X), or empty vector control
followed by co-immunoprecipitation using anti-GRIN2A
(Figure 1b). We observed that WT GRIN2A and to lesser
extent GRIN2A (R920K) precipitated GRIN1. However,
GRIN2A (W372X, Q891X, or W1271X) mutants showed a
lack of binding to GRIN1 corroborating our previous results.
The differences observed between binding of GRIN1 to
GRIN2A (W1271X) may be a result of the use of antibodies
directed toward GRIN1 or GRIN2A and their efficiencies or
epitope-binding domains. These results suggest that GRIN2A
somatic mutations resulting in truncated proteins reduce
proper complex formation with GRIN1. As GRIN2A ultimately
forms a cation channel, loss of such a complex formation
would result in decreased influx and ultimately attenuation of
the cation-dependent signaling mechanism.
NMDA receptors require proper complex formation
between GRIN1 and one of the many different GRIN2/3
subunits to allow for calcium influx into cells. We used a
co-expression assay in HEK293T cells to test whether calcium
influx into cells is affected by these mutations. Transiently
transfected HEK293T cells were analyzed for influx of calcium
upon stimulation with NMDA, a specific ligand for the NMDA
receptor. Cells expressing WT GRIN1 and WT GRIN2A, upon
stimulation with 200mM of NMDA, show proper NMDA
receptor function with an increase in calcium permeability
in the cells as a measure of fold change over time (Figure 1c,
top left panel). However, expression of GRIN1 with GRIN2A
(Q891X or R920K) results in nonfunctional NMDA receptors
(Figure 1c), confirming the previous results showing reduced
binding between GRIN1 and these mutants. Interestingly,
expression of GRIN1 with GRIN2A (W1271X) shows dimin-
ished calcium influx in transiently transfected cells (Figure 1c).
Our transient results demonstrate that proper complex forma-
tion is required between GRIN1 and GRIN2A for the calcium
channel to function appropriately. We hypothesize that func-
tional NMDA receptor signaling in melanoma cells containing
GRIN2A truncation mutations is lost resulting in diminished
activation of Ca2þ -dependent pathways, potentially leading
to increased survival through suppression of cell death
(excitotoxicity).
To determine the nature of the loss of functioning of these
mutations, we examined the ability of these mutations to inhibit
complex formation via a dominant negative effect. We co-
expressed WT GRIN1 and WT GRIN2A in the absence or
presence of mutated GRIN2A in a transient system. Figure 1d
shows that increased expression of mutant GRIN2A results in
loss of complex formation between WT GRIN1 and WT
GRIN2A compared with increased amounts of empty vector
transfected into cells. These results suggest that somatic muta-
tions of GRIN2A cause a loss of functioning potentially through
a dominant negative effect inhibiting normal NMDAR signaling
downstream to known effector molecules (e.g., p38 MAPK
(mitogen-activated protein kinase); Doronzo et al., 2010).
Hyperactivation of NMDA receptors via glutamate or
NMDA stimulation leads to prolonged influx of Ca2þ ions
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and hyperactivation of pro-apoptotic signaling mechanisms
(e.g., p38 MAPK activation) leading to reduced cell prolifera-
tion, migration, invasion, and even cell death in certain
cellular contexts (e.g., excitotoxicity; Wang et al., 2013). To
determine how somatic mutation of GRIN2A effects its ability
to activate Ca2þ -mediated signaling to pro-apoptotic
pathways, we co-expressed GRIN2A (WT or mutants) or
empty vector with GRIN1 (WT) in the presence of Ringer’s
solution and NMDA. Cells expressing WT GRIN1 and WT
GRIN2A had a significant increase in p38 MAPK activation
when stimulated with NMDA (Figure 1e). However, co-
expression of WT GRIN1 with any of the GRIN2A mutant
constructs or empty vectors resulted in little to no p38 MAPK
activation in the presence of NMDA (Figure 1e). These results
further corroborate our hypothesis that GRIN2A may function
as a tumor suppressor in melanoma cells whereby certain
somatic mutations cause attenuation of NMDAR-dependent
Ca2þ -mediated pro-apoptotic signaling.
To better understand how somatic mutations of GRIN2A
in melanoma affect its ability to potentiate tumorigenesis,
we created stable pooled clones expressing a subset of the
mutations initially tested. Two independent cell lines, 31T
and SK-Mel-2, were used to co-express GRIN1 and GRIN2A
(WT, W372X, Q891X, R920K, or W1271X) or empty vector
HEK293T transient expt HEK293T transient expt
250
(+ GRIN1 (WT)) (+ GRIN1 (WT))Ve
ct
or
Ve
ct
or
W
ild
 ty
pe
W
ild
 ty
pe
E3
71
K
W
37
2X
W
37
2X
E3
73
K
G
88
9E
Q8
91
X
Q8
91
X
R
92
0K
R
92
0K
E1
17
5K
W
12
71
X
W
12
71
X
kDa
150
100
75
50
IP: α-GRIN1
IB: α-GRIN2A
IP: α-GRIN2A
IB: α-GRIN2A
IP: α-GRIN1
α-GRIN2A
α-GRIN1
α-Tubulin
α-GRIN1
α-GADPH
IB: α-GRIN1
37
100
Lysates
Lysates
GRIN1 (WT)/GRIN2A (WT)
2.5
2.0
1.5
1.0
0.5
0.0
0 500 1,000
Time (sec)
1,500
GRIN1 (WT)/
GRIN2A (Q891X)
GRIN1 (WT)/
GRIN2A (R920K)
GRIN1 (WT)/
GRIN2A (W1271X)
Fo
ld
 c
ha
ng
e 
(Δ
R
FU
)
2.5
2.0
1.5
1.0
0.5
0.0
0 500 1,000
Time (sec)
1,500
Fo
ld
 c
ha
ng
e 
(Δ
R
FU
)
2.5
2.0
1.5
1.0
0.5
0.0
0 500 1,000
Time (sec)
1,500F
ol
d 
ch
an
ge
 (Δ
R
FU
)
2.5
2.0
1.5
1.0
0.5
0.0
0 500 1,000
Time (sec)
1,500
Fo
ld
 c
ha
ng
e 
(Δ
R
FU
)
HEK293T transient expt
GRIN1/GRIN2A
Vector
1 2 4 1 2 4 μg
W372X
IP: α-GRIN1
α-GRIN1
Wild type
W372X
α-GRIN2A
α-P-p38
α-p38
α-Tubulin
α-GRIN2A
α-GRIN2A
α-Tubulin
250
kDa
150
Lysate
100
75
50
50
250
kDa
150
100
75
50
HEK293T transient expt
+ GRIN1 (WT)Ve
ct
or
W
ild
 ty
pe
W
37
2X
Q8
91
X
R
92
0K
W
12
71
X
200 μM NMDA+ + + + + +
a b c
d e
Figure 1. Somatic mutations in GRIN2A have adverse effects on receptor function and formation. Mutant forms of GRIN2A-binding GRIN1 with reduced affinity
thus causing decreased NMDAR complex formation. (a) HEK293T cells were transiently transfected with wild-type (WT) GRIN1 and GRIN2A (WT or mutants) or
empty vectors as control and immunoprecipitated with anti-GRIN1. Immunoprecipitates (IPs) were probed with anti-GRIN2A and anti-GRIN1 to confirm binding.
Lysates were probed with anti-GRIN2A, and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) was used as a loading control. (b) HEK293T cells
were transiently transfected with WT GRIN1 and GRIN2A (WT or mutants) or empty vectors as control and immunoprecipitated with anti-GRIN2A.
Immunoprecipitates were probed with anti-GRIN1 and anti-GRIN2A to confirm binding. Lysates were probed with anti-GRIN1 and anti-GAPDH as a loading
control. (c) Influx of calcium upon N-methyl-D-aspartate (NMDA) stimulation of transient transfected HEK293T cells shows decreased calcium permeability in
cells expressing mutant forms of GRIN2A. Cells were pretreated with the Fluo-3/AM probe prior to imaging on Zeiss confocal microscope. Images were taken
every 5 seconds over a period of 15 minutes. NMDA (200mM) was added to the dishes at the 100 second mark. Graphs are fold increase in fluorescent signal vs.
time (seconds). Values are representative of 8–10 individual cells from the image view. (d) HEK293T cells were transiently co-transfected with WT GRIN1 and WT
GRIN2A and increasing amounts of empty vector or W372X and immunoprecipitated with anti-GRIN1. Immunoprecipitates were probed with anti-GRIN1 and
anti-GRIN2A to confirm binding. Lysates were probed with anti-GRIN1 and anti-GAPDH as a loading control (samples are on one gel but adjusted to be next to
each other in figure). (e) HEK293T cells were transiently co-transfected with WT GRIN1 and GRIN2A (WT or mutants) or empty vectors as control and stimulated
with 200mM NMDA in the presence of Ringer’s solution for 60 minutes. Lysates were probed with anti-P-p38 mitogen-activated protein kinase (MAPK), anti-p38
MAPK, and anti-GRIN2A to confirm expression. Lysates were probed with anti-tubulin as a loading control. Figures were adjusted to remove unwanted overall
background due to western blotting and film development. IB, immunoblot.
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control via sequential transduction and dual selection. We
tested for expression and the ability to form proper NMDAR
complexes in both cell lines (31T or SK-Mel-2) by immuno-
precipitating using either anti-GRIN2A or anti-GRIN1 and
analyzing via western blot analysis (Figure 2a and b,
respectively). GRIN2A expression was similar for GRIN2A,
W372X, Q891X, and W1271X in both cell lines; however,
there were some differences of expression for WT GRIN2A
and GRIN2A (R920K) between 31T and SK-Mel-2 cells.
GRIN1 was relatively equally expressed in both stable cell
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Figure 2. Melanoma cells expressing mutant forms of GRIN2A have increased ability for anchorage-independent growth. Stable melanoma cell lines
31T and SK-Mel-2 expressing wild-type (WT) GRIN1 and GRIN2A (WT or mutants) or empty vector control and immunoprecipitated with anti-GRIN1 and
anti-GRIN2A. Immunoprecipitates (IP) were probed with anti-GRIN2A and anti-GRIN1 to examine N-methyl-D-aspartate receptor (NMDAR) complexes in 31T
(a) or SK-Mel-2 (b). Melanoma cell line 31T cells (c) stably expressing GRIN1 and GRIN2A mutants or empty vector were seeded into Boyden chambers in
0.5% serum and grown for 48 hours before staining and counting. Melanoma cell line 31T cells (d) stably expressing GRIN1 and GRIN2A mutants or empty
vector were seeded into Boyden chambers plus and minus 10mM TCN-213 for 48 hours before staining and counting. Panels e and f are quantitative graphs
of colony formation of 31T and SK-Mel-2 cells in soft agar, respectively. Error bars are representative of n¼ 3 (SD) (*Po0.01, Student’s t-test). Figures were
adjusted to remove unwanted overall background due to western blotting and film development. IB, immunoblot.
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lines tested (Figure 2a and b). We observed normal complex
formation between WT GRIN1 and WT GRIN2A and to lesser
extent GRIN2A (R920K) in both stable cell lines (Figure 2a and
b). Conversely, expression of GRIN2A (W372X, Q891X, or
W1271X) resulted in loss of complex formation to WT GRIN1,
again observed in both stable cell lines. Furthermore, we
tested expression of WT or mutant forms of GRIN2A
on proliferation. Interestingly, little to no effect on cellular
proliferation in either the 2359 (31T) or SK-Mel-2 stable cell
lines was observed (Supplementary Figure S2 online).
To determine how expression of GRIN1 and GRIN2A (WT
or mutant) in melanoma affects melanoma biology, we used
cell migration and anchor-independent growth assays. Stable
pooled clones (31T or SK-Mel-2) expressing WT GRIN1 and
GRIN2A (WT or mutants) or empty vector were seeded into
Boyden chamber assays and grown for 24–48 hours prior to
analysis of a migratory phenotype. Expression of WT GRIN1
and WT GRIN2A in 31T caused reduced migration compared
with empty vector (Figure 2c). However, expression of mutant
GRIN2A (W372X, Q891X, R920K, and W1271X) showed
increased migration in 31T and SK-Mel-2 compared with both
WT GRIN2A and empty vector. Migration of 2359 cells
expressing WT GRIN2A was reversed in the presence of a
specific NMDAR2A (GRIN2A) antagonist, TCN-213. As seen
in Figure 2d, stable clones expressing WT GRIN2A migrated
significantly better in the presence of 10mM TCN-213 com-
pared with migration in the absence of antagonists. However,
vector- or mutant-expressing clones were unaffected by TCN-
213. SK-Mel-2 cells were tested for the ability to migrate using
multiple time points and cell numbers with no migration
phenotype observed at any point. Furthermore, we analyzed
the tumorigenic effect of the mutants in melanoma using an
anchorage-independent growth assay. Expression of WT
GRIN1 and WT GRIN2A in 31T and SK-Mel-2 caused
diminished colony formation compared with empty vector
(Figure 2e and f). Expression of GRIN2A mutants showed
increased soft agar colony formation, again in both 31T and
SK-Mel-2 stable clones. These results demonstrate that expres-
sion of somatically mutated forms of GRIN2A in melanoma
cells leads to an increased migration and colony formation
through the loss of tumor-suppressive activity via a NMDAR-
dependent Ca2þ influx.
To further delineate the role GRIN2A has in melanoma cell
biology, we stably depleted endogenous GRIN2A using short-
hairpin RNA (shRNA) and further functionally analyzed the
effects caused by knockdown. Using melanoma cell lines that
express WT GRIN2A (31T and 39T) or mutant GRIN2A
(E1175K) (501Mel and 125T) we stably transduced GRIN2A-
specific shRNAs: shRNA#1, #2, and #3) into each cell line and
a vector control (pLKO.1). As seen in Figure 3, GRIN2A is
knocked down at the message level by 20–70% as determined
by quantitative reverse transcriptase–PCR analysis in all cell
lines tested. We examined growth potential of cells depleted
of GRIN2A in WT or mutant backgrounds. Strikingly, shRNA
knockdown of WT GRIN2A resulted in increased proliferation
of cells stably transduced with shRNAs #1–3 compared with
cells transduced with pLKO.1 alone (Figure 3c and d). In
contrast, depletion of mutant GRIN2A caused a slight
reduction in proliferation compared with vector control cells
(Figure 3e and f); however, the level of knockdown in the
two mutant lines is notably less than the WT lines, possibly
indicating a higher level of cell dependency on this mutated
protein. These results support our hypothesis that WT GRIN2A
functions as a tumor suppressor in melanoma cells given the
increase in growth potential in cells devoid of only 50–60% of
total GRIN2A messenger RNA. Although further analyses of
the signaling mechanisms downstream of glutamate receptors
are needed, our study provides an insight into the biological
relevance of GRIN2A somatic mutations in melanoma and
reveals a possible node of clinical intervention for the
treatment of malignant melanoma.
DISCUSSION
Here we show in malignant melanoma the functional analysis
of the ionotropic glutamate receptor subunit, GRIN2A. On the
basis of previous whole-exome sequencing results, our lab
revealed GRIN2A to be highly mutated (Wei et al., 2011) in
melanoma demonstrating the importance that glutamate
signaling has in tumorigenesis. Recent work demonstrated
GRIN2A promoter methylation present in human colorectal
carcinoma (Kim et al., 2008). These researchers further
demonstrated that expression of WT GRIN2A with WT
GRIN1 resulted in suppressed cell growth in soft agar. In our
present study, we showed that somatic mutation of GRIN2A
resulted in decreased complex formation of the NMDAR
leading to increased migration and colony formation in soft
agar, whereas expression of WT GRIN2A acted as a tumor
suppressor in melanoma. Our results suggest that expression of
mutant forms of GRIN2A may have a protective role in
melanoma, potentially acting as a dominant negative
suppressing WT GRIN2A normal activity.
NMDAR signaling has opposing roles depending on the
partners that are found within the larger complex (Xiao et al.,
2011; Choo et al., 2012). Neurological cells use different
signaling mechanisms that function in a protective manner
and when overstimulated via glutamate (excitotoxic) result in
programmed cell death. NMDA receptor signaling uses
divalent cation influx (e.g., Ca2þ ) via glutamate/glycine
binding to mediate signaling to downstream elements
involved in survival and/or cell death pathways (Xiao et al.,
2011; Choo et al., 2012; Ru et al., 2012). Recently, it was
demonstrated that hippocampal cells, found in the central
nervous system, use differential signaling for either the p38
MAPK pathway or the Erk1/2 pathway depending on which
GRIN2 subunit is present in the NMDAR complex with
GRIN1 (Xiao et al., 2011). Immature hippocampi
preferentially express GRIN2B and upon stimulation of the
NMDAR activate the Erk1/2. Interestingly, these authors show
that mature hippocampi from rats mainly express GRIN2A
compared with GRIN2B and upon NMDAR stimulation
activate p38 MAPK signaling causing a more pronounced
neuronal cell death. The fact that we observed so many
somatic mutations causing truncated or nonfunctional versions
of GRIN2A may be one way that melanoma cells use to
potentiate a more proliferative and pro-survival phenotype; via
subunit switching to GRIN2B or a dominant negative effect.
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The functional domains found in GRIN2A have major roles
in Mg2þ -gated calcium channel influx of NMDA receptors.
Reports by Endele et al. (2010), Maki et al. (2013), and others
show that mutations found in both the GRIN2A or GRIN2B
result in reduced Mg2þ gating of the NMDAR causing
nonfunctional calcium signaling. Recent studies identified
that patients with epilepsy or encephalopoathies harbor
germline mutations in NMDAR2A (GRIN2A) (Carvill et al.,
2013; Lemke et al., 2013; Lesca et al., 2013). Interestingly, the
spectrum of the identified mutations was very similar to the
ones we observed with multiple non-synonymous mutations
resulting in missense and nonsense alterations. Mutations
observed in these patients also resulted in decreased or
aberrant calcium (ion) influx. Another study by the Kutsche
group examined patients with neurological disorders ranging
from mental retardation to epilepsy. They discovered that
mutations found in GRIN2A (W218X or N615K) resulted in
truncated or nonfunctional subunits of the NMDA receptor
leading ultimately to reduced calcium channel permeability.
GRIN2B was also shown to carry several mutations that
disrupted its functionality, resulting in reduced NMDA
receptor signaling. Maki et al. (2013) showed that alanine
screening for potentially important residues in the C-terminal
domain of GRIN2A revealed two important sites of
phosphorylation, Ser900 and Ser929. Mutation of GRIN2A at
either site resulted in reduced calcium channel conductance
potentially causing reduced signaling. Interestingly, we found
one of the same sites to be somatically mutated (Ser929Phe)
in our malignant melanoma samples (Wei et al., 2011;
Supplementary Figure S1 online). These results not only
corroborate our findings that somatic mutations in GRIN2A
result in loss of function in calcium channel signaling but also
reveal the importance of proper NMDAR signaling in brain
(neuronal) and melanocyte development and survival. Future
functional analyses are required to further examine the role
that GRIN2A may have in the etiology of the disease. This
would allow a better understanding of the already established
importance that NMDA receptor signaling has in melanoma.
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Figure 3. GRIN2A functions as a tumor suppressor in melanoma cells. Stable depletion of endogenous GRIN2A in melanoma cells. Melanoma cells stably
depleted of endogenous GRIN2A were confirmed via quantitative reverse transcriptase–PCR of all clones. (a, b) Analysis of knockdown used specific GRIN2A
primers and efficiency was compared with glyceraldehyde-3-phosphate dehydrogenase levels in each sample, thus generating a fold change. Proliferation assay of
WT 31T (c) or 39T (d) and mutant 501Mel (e) or 125T (f) expressing GRIN2A cell lines depleted of GRIN2A. Knockdown resulted in little to no change in
proliferation for 125T or 501Mel melanoma cell lines expressing mutant GRIN2A but increased proliferation for both 31T and 39T cell lines expressing WT
GRIN2A. Each cell line used pLKO.1 as an empty vector control.
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MATERIALS AND METHODS
Construction of WT and mutant GRIN2A expression vectors
Mouse GRIN1 (BC039157) and mouse GRIN2A (BC148800) were
cloned by PCR as previously described (Palavalli et al., 2009) using
clones (MMM4769-202766680 (GRIN1) or OMM5895-202524480
(GRIN2A)) purchased from Open Biosystems (Huntsville, AL) with
primers listed in Supplementary Table S1 online. The PCR products
were cloned into the mammalian expression vectors pCDF-MCS2-
EF1-Puro or pCDH1-MCS-CMV-Neo (Systems Biosciences, Mountain
View, CA) via the XbaI and NotI restriction sites. Point mutations were
introduced as previously described (Prickett et al., 2009) using the
primers found in Supplementary Table S1 online.
Cell culture and transient expression
HEK293T cells were purchased from ATCC (Manassas, VA) and
maintained in complete RPMI-1640 medium supplemented with 10%
FBS. HEK293T cells were transfected with Arrest-IN reagent (Open
Biosystems) at a 6:1 ratio with DNA (ml:mg) using 2–6mg of plasmid
DNA. Ringer’s solution was obtained from the veterinary pharmacy at
the National Institutes of Health. All experiments were conducted in
accordance with institutional guidelines.
Immunoprecipitation and western blotting
Transfected cells were gently washed two times in phosphate-
buffered saline and then lysed using 1.0 ml 1% NP-40 lysis buffer
(1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, complete
protease inhibitor tablet, EDTA-free (Roche, Indianapolis, IN), 1mM
sodium orthovanadate, 1 mM sodium fluoride, and 0.1% b-mercapto-
ethanol) per T75 flask for 20 minutes on ice. Lysed cells were scraped
and transferred into a 1.5 ml microcentrifuge tube. Extracts were
centrifuged for 10 minutes at 14,000 r.p.m. at 4 1C. Next, 800ml of
supernatant was immunoprecipitated overnight using 20ml of anti-
GRIN1 and 30ml of 50% slurry of protein A/G beads (Roche).
The immunoprecipitates were washed and subjected to SDS-PAGE
and western blotting as previously described (Palavalli et al., 2009).
Primary antibodies used in our signal transduction pathway analysis
were anti-GRIN1 (sc162902), anti-GRIN2A (sc1468), or anti-GRIN2A
(sc-136004) (Santa Cruz Biotechnology, Dallas, TX), anti-P-p38
MAPK (#9211), anti-p38 (#9212) (Cell Signaling), and anti-GAPDH
(#CB1001) (Calbiochem-EMD Biosciences, San Diego, CA).
Pooled stable expression
To make lentiviruses, GRIN1 or GRIN2A constructs were co-trans-
fected into HEK293T cells seeded at 1.5 106 per T75 flask with
pVSV-G and pFIV-34N (kind gifts from Todd Waldman, Georgetown
University) helper plasmids for pCDF1 based or pPACKH1 viral
production mixture from SBI (Mountain View, CA) for pCDH1 based
using Arrest-IN as described by the manufacturer. Virus-containing
medium was harvested 60 hours after transfection, filtered, aliquoted,
and stored at  80 1C. 31T cells (kind gift from Dr Rosenberg) were
grown in RPMI-1640 (Lonza, Walkersville, MD) and supplemented
with 10% FBS (HyClone, Logan, UT). A375 cells were purchased
from National Cancer Institute, Division of Cancer Treatment,
Developmental Therapeutics Program, Frederick, MD and maintained
in RPMI-1640 and supplemented with 10% FBS. 31T or SK-Mel-2
cells were seeded at 1.5 106 cells per T75 flask 24 hours prior to
infection. Lentivirus for GRIN1 and GRIN2A (WT or mutants)
and empty vector control were used to sequentially infect 31T or
SK-Mel-2 cells as previously described (Prickett et al., 2009). Stable
expression of GRIN1 proteins (WT) was determined by immuno-
precipitation and SDS-PAGE analysis followed by immunoblotting
with anti-GRIN1 and anti-GAPDH to show equivalent expression
among pools. Stable expression of GRIN2A (WT or mutants) was
determined by reverse transcriptase–PCR analysis of messenger RNA
from 31T or SK-Mel-2 stable pooled clones using GRIN2A-specific
primers and GAPDH primers as a loading control.
Proliferation assays
To examine growth potential, pooled 31T or SK-Mel-2 pooled clones
were seeded into 96-well plates at 300 cells per well in either 1, 2.5,
or 10% serum-containing medium and incubated for 13–17 days.
Samples were analyzed every 48 hours by lysing cells in 50ml of 0.2%
SDS per well and incubating for 2 hours at 37 1C prior to addition of
150ml per well of SYBR Green I solution (1:750 SYBR Green I
(Invitrogen, Molecular Probes, Carlsbad, CA) diluted in dH20). Plates
were analyzed using a BMG Labtech (Cary, NC) FLOUstar Optima.
Migration assays
31T or SK-Mel-2 pooled clones were seeded into preconditioned
migration wells (8.0mm—BD Biocoat, BD Biosciences, San Jose, CA)
at 30,000–100,000 cells per well in serum-free medium in the top
chamber and incubated for 24–48 hours with complete serum-con-
taining medium in the bottom chamber before harvesting. Antagonist
studies used 10mM of TCN-213 (Tocris, Minneapolis, MN) dissolved in
DMSO in the top and bottom chambers of the Boyden chamber.
DMSO was used as a negative control for this assay usingo0.02%
(vol/vol). Inserts were fixed and stained using Hema 3 Stat Pack (Fisher
Scientific, Pittsburgh, PA) as per the manufacturer’s protocol. Inserts
were analyzed and counted for cells migrated per field view and
quantitated using ImageJ (National Institutes of Health, Bethesda, MD).
Soft agar assay
31T or SK-Mel-2 pooled clones were plated in triplicate at 1000 cells
per well and in top plugs consisting of sterile 0.33% Bacto-Agar (BD,
Sparks, MD) and 10% FBS (HyClone, Logan, UT) in a 24-well plate.
The lower plug contained sterile 0.5% Bacto-Agar and 10% FBS.
After 2 weeks, the colonies were photographed and quantitated using
ImageJ (NIH software).
Lentiviral shRNA
Constructs for stable depletion of GRIN2A (cat#RHS4533-EG2903)
were obtained from Open Biosystems and were confirmed to
efficiently knockdown GRIN2A at the message level. Lentiviral stocks
were prepared as previously described (Prickett et al., 2009).
Melanoma cell lines (31T, 39T, 501Mel, or 125T) were infected
with shRNA lentiviruses for each condition (vector and 2–3 different
GRIN2A-specific shRNAs). Selection of stable pooled clones was
carried out in the presence of 3mg ml 1 puromycin-containing
normal medium for 3–5 days prior to determining knockdown
efficiency. Stably infected pooled clones were tested in functional
assays.
Reverse transcription PCR
Total RNA was extracted from pooled clones of melanoma cells
stably knocked down for endogenous GRIN2A following the manu-
facturer’s protocol for the RNeasy Mini Kit (QIAGEN #74101,
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Gaithersburgh, MD). Total RNA was eluted in 30ml diethylpyrocar-
bonate-treated distilled H2O. A total of 1mg of total RNA was used for
single-strand complementary DNA synthesis using a SuperScript III
First Strand kit (Invitrogen #18080-051). Complementary DNA was
amplified using the olido dT20 primer supplied in the kit. To test for
loss of GRIN2A message, we used 1ml of complementary DNA in the
PCR reaction with either GRIN2A primers or GAPDH primers
(Supplementary Table S2 online).
Proliferation assays of stable knockdown cells
To examine growth potential, stable pooled knockdown clones for
GRIN2A were seeded into 96-well plates at 500 cells per well in
either 1, 2.5, or 10% serum-containing medium and incubated for 6–
8 days. Samples were analyzed every 2–3 days by lysing cells in 50ml
of 0.2% SDS per well and incubating for 2 hours at 37 1C prior to
addition of 150ml per well of SYBR Green I solution (1:750 SYBR
Green I (Invitrogen-Molecular Probes) diluted in dH2O). Plates were
analyzed using a BMG Labtech FLOUstar Optima.
Calcium assays
HEK293T cells seeded in 35 mm glass-bottomed culture dishes
(MatTek, Ashland, MA) were transiently transfected with GRIN1 and
either GRIN2A WT or mutants (Q891X, R920K, W1271X). Thirty-six
hours post-transfection cells were washed with Tyrode solution (5 mM
HEPES, 136 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.9 mM CaCl2, 5.6 mM
glucose, buffered to pH 7.4 with Tris base). Cells were loaded with
10mM Fluo-3AM diluted in Tyrode supplemented with 0.1% BSA for
45 minutes in the dark, followed by two washes with Tyrode-BSA and
two washes with Tyrode alone. Loaded cells were then left for
15 minutes to ensure complete hydrolysis of the acetoxymethyl ester
groups. Images were taken every 5 seconds over a period of 15 min-
utes and collected on a Zeiss LSM-700 laser scanning microscope
(Thornwood, NY) with a  63 oil immersion lens in a single track
mode using excitation 488 nm and emission BP 505-530 filter sets.
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